Skip to content

Xencor XNCR Free cash flow yield

Free cash flow yield at other companies

Amgen logo
AmgenAMGN
4.5%-2.0pp
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
5%+0.6pp
Janux Therapeutics logo
Janux TherapeuticsJANX
-9.3%-17.1pp
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-17.9%-2.6pp
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
0.3%+0.1pp
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-5.5%-1.2pp

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.09B+79.8%
Enterprise value$1.25B+58.6%
P/S11.2×+6.4×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Calculated from Xencor’s reported figures.

Based on trailing twelve months.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's free cash flow yield?
Xencor (XNCR) reported free cash flow yield of -21.4% in Q1 2026.
How has Xencor's free cash flow yield changed year-over-year?
Xencor's free cash flow yield increased by 5.3% year-over-year, from -22.5% to -21.4%.
What is the long-term trend for Xencor's free cash flow yield?
Over 2 years (2022 to 2025), Xencor's free cash flow yield has grown at a 275.3% compound annual growth rate (CAGR), from -0.9% to -12.6%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.